Adheris Health Limited (ASX:AHE)
Australia · Delayed Price · Currency is AUD | Market Cap | 10.83M -86.1% |
| Revenue (ttm) | 40.60M -51.4% |
| Net Income | -54.26M |
| EPS | -0.09 |
| Shares Out | 637.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,602 |
| Open | 0.0170 |
| Previous Close | 0.0170 |
| Day's Range | 0.0170 - 0.0170 |
| 52-Week Range | 0.0170 - 0.0920 |
| Beta | 1.00 |
| Analysts | Hold |
| Price Target | 0.19 (+1,017.65%) |
| Earnings Date | Apr 28, 2026 |
About Adheris Health
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts. [Read more]
Financial Performance
Financial StatementsNews
Adheris Health Earnings Call Transcript: Q3 2026
Q3 saw lower revenue and margins, but cost reductions and digital expansion are driving a return to stability. Cash flow is targeted to be neutral in Q4, with profitability expected in FY 2027 and no need for new capital.
Adheris Health Earnings release: Q3 2026
Adheris Health released its Q3 2026 earnings on April 28, 2026, summarizing the period's financial results.
Adheris Health Slides: Q3 2026
Adheris Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 28, 2026.
Adheris Health Quarterly report: H1 2026
Adheris Health has published its H1 2026 quarterly earnings report on February 26, 2026.
Adheris Health Earnings release: H1 2026
Adheris Health released its H1 2026 earnings on February 26, 2026, summarizing the period's financial results.
Adheris Health Earnings release: Q2 2026
Adheris Health released its Q2 2026 earnings on January 28, 2026, summarizing the period's financial results.
Adheris Health Transcript: AGM 2025
The meeting addressed a challenging year marked by a statutory loss, ANZ divestiture, and U.S. revenue decline. Strategic priorities include cost reduction, digital expansion, and product innovation. All resolutions were put to a poll, with results to be announced to the ASX.
Adheris Health Slides: FY 2025
Adheris Health has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 25, 2025.
Adheris Health Earnings Call Transcript: Q1 2026
Q1 saw significant revenue and margin declines due to regulatory delays, policy pressures, and market headwinds, especially in vaccines. The business is now focused on U.S. transformation, cost optimization, and digital innovation, with specialty medications expected to drive future growth.
Adheris Health Earnings release: Q1 2026
Adheris Health released its Q1 2026 earnings on October 21, 2025, summarizing the period's financial results.
Adheris Health Slides: Q1 2026
Adheris Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on October 21, 2025.
Adheris Health Annual report: H2 2025
Adheris Health has published its H2 2025 annual report on October 9, 2025.
Adheris Health Earnings release: H2 2025
Adheris Health released its H2 2025 earnings on October 9, 2025, summarizing the period's financial results.
Adheris Health Slides: Investor Presentation
Adheris Health has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2025.
Adheris Health Transcript: AGM 2025
The meeting addressed 14 resolutions, with notable shareholder protest votes against executive incentives and retention benefits. Key risks discussed included executive retention and morale, with the Chair emphasizing transparency and the need for stability during strategic changes.
Adheris Health Earnings Call Transcript: Q4 2025
FY 2025 results were impacted by U.S. program delays and industry headwinds, leading to a revenue decline and revised guidance. The ANZ business was sold, strengthening the balance sheet, while FY 2026 targets 15% revenue growth and reduced costs amid ongoing strategic review.
Adheris Health Earnings release: Q4 2025
Adheris Health released its Q4 2025 earnings on July 30, 2025, summarizing the period's financial results.
Adheris Health Slides: Q4 2025
Adheris Health has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on July 30, 2025.
Adheris Health Transcript: Investor Update
A strategic review led to the sale of the ANZ business for up to AUD 42.35 million, eliminating debt and leaving a strong cash position. The U.S. business is now the focus, with ongoing review and growth initiatives, and the Board is considering capital management options.
Adheris Health Press release: Investor Update
Adheris Health issued a press release on July 7, 2025, disclosing material business information to investors.
Half Year 2025 MedAdvisor Ltd Earnings Presentation Transcript
Half Year 2025 MedAdvisor Ltd Earnings Presentation Transcript